New 'Living Drug' trial targets tough blood cancers
NCT ID NCT07234110
Summary
This early-stage study is testing the safety and finding the right dose of a new experimental treatment called CD5CART for adults with advanced blood cancers that have returned or stopped responding to standard therapies. The treatment involves collecting a patient's own immune cells, genetically modifying them in a lab to target cancer cells, and then infusing them back into the patient. The main goals are to see if the treatment is safe and to measure how well it works against these difficult-to-treat cancers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED AND REFRACTORY CD5 HEMATOLOGICAL TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hematology Hospital of Chinese Academy of Medical Sciences
RECRUITINGTianjin, Tianjin Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.